Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL DRUGS FOR MALARIA INDUSTRY
2.1 Summary about Drugs for Malaria Industry
2.2 Drugs for Malaria Market Trends
2.2.1 Drugs for Malaria Production & Consumption Trends
2.2.2 Drugs for Malaria Demand Structure Trends
2.3 Drugs for Malaria Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Aryl Aminoalcohol Compounds
4.2.2 Antifolate Compounds
4.2.3 Artemisinin Compounds
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Prevention
4.3.2 Treatment
4.3.3 Others
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Aryl Aminoalcohol Compounds
5.2.2 Antifolate Compounds
5.2.3 Artemisinin Compounds
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Prevention
5.3.2 Treatment
5.3.3 Others
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Aryl Aminoalcohol Compounds
6.2.2 Antifolate Compounds
6.2.3 Artemisinin Compounds
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Prevention
6.3.2 Treatment
6.3.3 Others
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Aryl Aminoalcohol Compounds
7.2.2 Antifolate Compounds
7.2.3 Artemisinin Compounds
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Prevention
7.3.2 Treatment
7.3.3 Others
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Aryl Aminoalcohol Compounds
8.2.2 Antifolate Compounds
8.2.3 Artemisinin Compounds
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Prevention
8.3.2 Treatment
8.3.3 Others
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Aryl Aminoalcohol Compounds
9.2.2 Antifolate Compounds
9.2.3 Artemisinin Compounds
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Prevention
9.3.2 Treatment
9.3.3 Others
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Guilin Pharmaceutical
10.1.2 Cipla
10.1.3 IPCA Laboratories
10.1.4 GlaxoSmithKline
10.1.5 Mylan Labs
10.1.6 Roche
10.1.7 Novartis
10.1.8 Sanofi Aventis
10.1.9 Ajanta Pharma
10.2 Drugs for Malaria Sales Date of Major Players (2017-2020e)
10.2.1 Guilin Pharmaceutical
10.2.2 Cipla
10.2.3 IPCA Laboratories
10.2.4 GlaxoSmithKline
10.2.5 Mylan Labs
10.2.6 Roche
10.2.7 Novartis
10.2.8 Sanofi Aventis
10.2.9 Ajanta Pharma
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
